Literature DB >> 32010347

THE EFFECT OF GLUCOVANCE THERAPY ON BIOMECHANICAL DETERIORATION OF BONE IN STREPTOZOTOCIN-INDUCED DIABETIC RATS.

C Demirel1, H Korkmaz2, S Gurgul1, A Yildiz3, E Akarsu4, N Erdal5.   

Abstract

AIM: Is to evaluate the influence of glucovance therapy on biomechanical properties of bone in streptozotocin - induced diabetes mellitus (DM) in rats.
MATERIALS AND METHODS: A total of 28 male Wistar-Albino rats (12-week-old; 210-300 g) were divided into 4 groups including control (C; no treatment; n=7), sham [Sh; distilled water (gavage, for 8 weeks); n=7], diabetes [DM; streptozotocin (45 mg/kg, single i.p injection); n=7] and diabetes+ Glucovance treatment [DM+G; streptozotocin (45 mg/kg, single i.p injection) + Glucovance (Glucovance, 500/5 mg/kg/day/rat, gavage, for 8 weeks); n=7] groups. Body weight, blood glucose levels (BGLs), bone mineral density (BMD) and geometric/mechanical properties of bone tissue were evaluated. BGLs in diabetic rats were significantly increased compared to non-diabetic rats, while the body weights were decreased (p<0.05).
RESULTS: A significant difference was not detected between groups with regard to cross-sectional area of diaphyseal femur (p>0.05). Maximum load, energy absorption capacity, ultimate stress, ultimate strain, toughness and displacement were shown to decrease and stiffness was shown to increase in DM rats (p<0.05). Ultimate stress and maximum load were significantly increased in DM+G groups compared to DM groups (p<0.05).
CONCLUSION: Glucovance treatment seems to be effective in restoration of biomechanical deterioration of bone specific to STZ-induced DM. ©by Acta Endocrinologica Foundation.

Entities:  

Keywords:  Diabetes mellitus; biomechanical; bone; bone mineral density; geometric; glucovance

Year:  2019        PMID: 32010347      PMCID: PMC6992399          DOI: 10.4183/aeb.2019.301

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  26 in total

1.  Analysis of biomechanical effects on bone and on the muscle-bone interactions in small animal models.

Authors:  J L Ferretti; G R Cointry; R F Capozza; R Capiglioni; M A Chiappe
Journal:  J Musculoskelet Neuronal Interact       Date:  2001-03       Impact factor: 2.041

2.  Deterioration of bone quality by long-term magnetic field with extremely low frequency in rats.

Authors:  Serkan Gürgül; Nurten Erdal; S Necat Yilmaz; Altan Yildiz; Handan Ankarali
Journal:  Bone       Date:  2007-09-06       Impact factor: 4.398

3.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

Review 4.  Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.

Authors:  Mohsen Janghorbani; Rob M Van Dam; Walter C Willett; Frank B Hu
Journal:  Am J Epidemiol       Date:  2007-06-16       Impact factor: 4.897

Review 5.  Bone as a target of type 2 diabetes treatment.

Authors:  Beata Lecka-Czernik
Journal:  Curr Opin Investig Drugs       Date:  2009-10

Review 6.  Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.

Authors:  M Saito; K Marumo
Journal:  Osteoporos Int       Date:  2010-02       Impact factor: 4.507

7.  Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.

Authors:  Bernard Zinman; Steven M Haffner; William H Herman; Rury R Holman; John M Lachin; Barbara G Kravitz; Gitanjali Paul; Nigel P Jones; R Paul Aftring; Giancarlo Viberti; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2009-10-29       Impact factor: 5.958

Review 8.  The contribution of the organic matrix to bone's material properties.

Authors:  D B Burr
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

9.  Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Authors:  Steven E Kahn; Bernard Zinman; John M Lachin; Steven M Haffner; William H Herman; Rury R Holman; Barbara G Kravitz; Dahong Yu; Mark A Heise; R Paul Aftring; Giancarlo Viberti
Journal:  Diabetes Care       Date:  2008-01-25       Impact factor: 19.112

10.  The mineral and mechanical properties of bone in chronic experimental diabetes.

Authors:  T A Einhorn; A L Boskey; C M Gundberg; V J Vigorita; V J Devlin; M M Beyer
Journal:  J Orthop Res       Date:  1988       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.